We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267).
1. What are the major unmet needs in current neoadjuvant chemotherapy regimes for women undergoing dual HER2 blockade for stage II–III HER2-positive breast cancer? (0:06)
2. Could you give us a brief overview of the TRAIN-2 study and its major findings? (1:08)
3. What have the long-term findings of this study taught us about the use of anthracyclines? (4:56)
4. What questions will the TRAIN-3 study address? (5:48)
5. What other approaches should be investigated in this treatment setting? (7:10)
Speaker disclosure: Anna van der Voort has no financial or non-financial relationships or activities to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
Share this Video
Related Videos In Breast Cancer
Javier Cortés, ESMO 2021: Results of the Randomized Phase III DESTINY-Breast03 Study
touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study. Questions 1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17) 2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55) 3. Could you tell us a little […]
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!